Literature DB >> 939070

Effect of sotalol on haemodynamics and renin-angiotensin-aldosterone system in hypertensive patients.

A Verniory, M Staroukine, F Delwiche, M Telerman.   

Abstract

1. Twenty-three hypertensive patients were treated by sotalol, a pure beta-adrenergic receptor blocking agent. The drug produced a significant decrease of blood pressure in nineteen patients. 2. On average, cardiac index decreased but not significantly; heart rate decreased and stroke index increased significantly. Total peripheral resistance varied in both directions. 3. Sotalol determined a fall in plasma renin concentration (only significant in the high-renin group), a fall in plasma angiotensin II concentration and in urinary excretion rate of aldosterone accompanied by a rise in plasma potassium concentration. 4. The fall of blood pressure was not correlated with the decreases of renin and angiotensin II concentrations or excretion rate of aldosterone. However, in the placebo period plasma angiotensin II concentration was significantly correlated with total peripheral resistance; during sotalol treatment the variations of these two parameters seemed also to be correlated. 5. There was a poor correlation between decreases of cardiac output and of blood pressure; it was impossible to foresee the magnitude of the lowering of the blood pressure from the initial cardiac index. 6. The association of a diuretic with sotalol enhanced the hypotensive effect of the beta-receptor blocking drug, without significant increase of plasma renin and angiotensin II concentrations.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 939070     DOI: 10.1042/cs0510009

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  7 in total

1.  The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise.

Authors:  P J Lijnen; A K Amery; R H Fagard; T M Reybrouck; E J Moerman; A F De Schaepdryver
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

Review 2.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  Fixed combination of sotalol and hydrochlorothiazide in the treatment of uncomplicated hypertension.

Authors:  A Jäättelä
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 4.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Comparison of the effects of atenolol, sotalol and labetalol on muscle blood flow in man.

Authors:  G V Raman; F M Mwongera; D J Warren
Journal:  Postgrad Med J       Date:  1986-09       Impact factor: 2.401

6.  Correlation between propranolol in plasma and urine, renin-aldosterone system and blood pressure in essential hypertension.

Authors:  E B Pedersen; H J Kornerup; O L Pedersen; F Andreasen; P Bjerregaard
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Effects of acute and long-term beta-adrenoceptor blockade with propranolol on haemodynamics, plasma catecholamines and renin in essential hypertension.

Authors:  M A van Baak; T L Kho; H Thijssen; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.